Royalty Pharma plc
About Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $2.4B
- Net income
- $770.9M
- Total assets
- $19.6B
- Market cap
- $24.8B
- Operating margin
- 65.6%
- Net margin
- 55.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.4B
- Operating expenses
- $818.7M
- Operating income
- $1.6B
- Income tax
- $0
- Net income
- $1.3B
- EPS (basic)
- $1.79
- EPS (diluted)
- $1.78
Balance sheet
- Total assets
- $19.6B
- Current assets
- $1.5B
- Total liabilities
- $9.9B
- Current liabilities
- $636.2M
- Shareholders’ equity
- $9.7B
Cash flow
- Operating cash flow
- $2.5B
- Investing cash flow
- -$1.6B
- Financing cash flow
- -$1.2B
- Net cash flow
- -$310.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $24.8B
- P/E ratio
- 30.8
- EPS (diluted)
- $1.78
- Dividend yield
- 1.71%
- Shares outstanding
- 451.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 16, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $770.9M in FY2025.
- Revenue grew 12% from FY2020 to FY2025.
- Trading near its 52-week high.
- Pays a dividend yielding about 1.71% annually.
- Valued at a price-to-earnings (P/E) ratio of 30.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Royalty Pharma plc.
Write a review
News about Royalty Pharma plc
News & sentiment via Polygon.io
